KemPharm Inc (NASDAQ:KMPH) reached a new 52-week low during trading on Thursday . The company traded as low as $1.60 and last traded at $1.63, with a volume of 2850 shares. The stock had previously closed at $1.64.
Separately, Zacks Investment Research cut KemPharm from a “hold” rating to a “sell” rating in a research note on Tuesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $10.75.
The firm has a market cap of $42.96 million, a PE ratio of -0.65 and a beta of 1.72.
COPYRIGHT VIOLATION WARNING: This report was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2019/04/18/kempharm-kmph-hits-new-52-week-low-at-1-60.html.
About KemPharm (NASDAQ:KMPH)
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Featured Article: Front-End Load
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.